{"id":26473,"date":"2022-03-31T20:37:06","date_gmt":"2022-03-31T15:37:06","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=89265"},"modified":"2022-03-31T20:37:06","modified_gmt":"2022-03-31T15:37:06","slug":"junshi-biosciences-announces-full-year-2021-financial-results-and-provides-corporate-updates","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/junshi-biosciences-announces-full-year-2021-financial-results-and-provides-corporate-updates\/","title":{"rendered":"Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates"},"content":{"rendered":"
-Tackling the COVID-19 pandemic challenge with multi-pronged strategies<\/em><\/p>\n –<\/em>\u00a0Pipeline progressed and expanded substantially<\/em><\/p>\n SHANGHAI, China, March 31, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences,\u201d HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced financial results for the full year 2021 and provided corporate updates.<\/p>\n Full Year 2020 Financial Highlights<\/strong><\/p>\n Business Highlights<\/strong><\/p>\n During the year 2021 and 2022 to date, Junshi Biosciences continuously adhered to the strategic plan of \u201cInternational layout with a base in China,\u201d and has achieved significant growth in operating income, which gradually demonstrated its \u201cincome generation\u201d capability. In addition, several of its R&D pipelines have reached key milestones. Junshi has also achieved progress with respect to product commercialization, clinical trials and pipeline expansion, including the following achievements and milestones:<\/p>\n About Junshi Biosciences<\/strong> In the face of the pandemic, Junshi Biosciences\u2019 response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the\u00a0Institute of Microbiology of the Chinese Academy\u00a0of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (\u201cEUA\u201d) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company\u2019s continuous innovation for disease control and prevention of the global pandemic.<\/p>\n Junshi Biosciences has over 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit:\u00a0http:\/\/junshipharma.com<\/a>.<\/p>\n Junshi Biosciences Contact Information<\/strong> Goby Global\n
\n
\n
\n
\n
\n
\n
\nFounded in\u00a0December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib\/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in\u00a0China\u00a0to be approved for clinical trials by the NMPA.<\/p>\n
\nIR Team:
\nJunshi Biosciences
\ninfo@junshipharma.com<\/a>\u00a0<\/u>
\n+ 86 021-2250 0300<\/p>\n
\nBob Ai
\nbai@gobyglobal.com<\/a>
\n+ 1 646-389-6658<\/p>\n